Compare PRMB & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRMB | SRRK |
|---|---|---|
| Founded | 1955 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 6.8B |
| IPO Year | 2025 | 2018 |
| Metric | PRMB | SRRK |
|---|---|---|
| Price | $20.82 | $54.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | $24.00 | ★ $56.17 |
| AVG Volume (30 Days) | ★ 4.1M | 967.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ 328.57 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $6,664,000,000.00 | N/A |
| Revenue This Year | $2.34 | N/A |
| Revenue Next Year | $3.56 | $534.24 |
| P/E Ratio | $84.19 | ★ N/A |
| Revenue Growth | ★ 29.34 | N/A |
| 52 Week Low | $14.36 | $27.07 |
| 52 Week High | $26.21 | $61.76 |
| Indicator | PRMB | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 37.82 | 49.26 |
| Support Level | $17.90 | $44.26 |
| Resistance Level | $21.33 | $58.49 |
| Average True Range (ATR) | 0.87 | 2.36 |
| MACD | -0.18 | -0.35 |
| Stochastic Oscillator | 16.02 | 9.47 |
Primo Brands Corp is a North American branded beverage company focused on healthy hydration. It delivers sustainably and domestically sourced diversified offerings across products, formats, channels, price points, and consumer occasions, distributed in every state and Canada. Primo Brands is in reusable packaging, helping to reduce waste through its reusable, multi-serve bottles and brand packaging portfolio, which includes recycled plastic, aluminum, and glass.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.